Analyst Says FDA First-Line Approval Of Takeda/Millennium’s Velcade No Surprise
This article was originally published in PharmAsia News
Executive Summary
TOKYO - The U.S. FDA's approval of Millennium Pharmaceuticals' Velcade (bortezomib) injection indicated for first-line treatment of multiple myeloma comes as no surprise to those analyzing the pharmaceutical industry
You may also be interested in...
Takeda Faces Serial FDA Delays, Yen Appreciation And Acquisition Drags In 2008
Japanese firm incurs “income contraction” for the first time in 17 years.
Takeda Copes With FDA Delays, Yen Appreciation and Acquisition Drags in 2008
TOKYO - U.S. FDA has moved back its PDUFA date on yet another Takeda drug - this time dipeptidyl peptidase-4 inhibitor SYR-322 (alogliptin) - making it the third Takeda drug facing FDA delays this year, Takeda President Yasuchika Hasegawa told a Nov. 4 earnings conference
Takeda Faces Serial FDA Delays, Yen Appreciation And Acquisition Drags In 2008
Japanese firm incurs “income contraction” for the first time in 17 years.